Firefly Neuroscience, Inc. (AIFF) AI Stock Analysis

Firefly Neuroscience, Inc. is an artificial intelligence company that develops, markets, and distributes medical devices and technologies in North America. Its primary offering is the Evoke System, which performs electroencephalographic (EEG) and event-related potential (ERP) assessments. These assessments are analyzed via its cloud-based platform and delivered as structured reports to support clinical decisions. The technology addresses various conditions, including depression, anxiety, ADHD, PTSD, dementia, Parkinson's disease, bipolar disorder, and traumatic brain injury. Founded in 2006 and based in Kenmore, New York, the company employs 17 people and primarily serves clinicians.

Firefly Neuroscience reported trailing twelve-month revenue of $1.8M as of June 30, 2026, with quarterly revenue growing 71.9% year-over-year. Historically, annual revenue declined from $13.9M in FY2020 to $32,000 in FY2021 before recovering to $498,000 in FY2023. Revenue fell to $108,000 in FY2024 but rebounded 957.4% to $1.1M in FY2025. Over the four years from FY2020 to FY2025, revenue contracted at a compound annual rate of -46.5%. Operating margin stood at -753.5% in FY2025, an improvement from -8500.0% in FY2024. Net loss widened to -$19.9M in FY2025 from -$10.5M in FY2024, while trailing twelve-month diluted EPS was -$0.59.

As of June 30, 2026, Firefly Neuroscience held $9.2M in cash and short-term investments, with total assets of $16.8M and shareholders' equity of $14.7M. The company maintains short-term liquidity with a current ratio of 4.87. Operating cash flow in FY2025 was -$8.2M, resulting in free cash flow of -$8.3M after capital expenditures of $128,000. In addition, the company directed $1.5M toward research and development expenses during FY2025.

Firefly Neuroscience has a market cap of $16.0M and an enterprise value of $16.9M. The stock trades at a price-to-sales multiple of 8.9x and an EV-to-revenue multiple of 9.4x, which are both elevated compared to the median of its US-listed Technology peers at 2.8x. Its price-to-book ratio is 1.2x. Over the past year, the stock fell 61.2%, while the S&P 500 (SPY) returned 16.8%. Over a five-year timeframe, the stock declined 98.9% compared to an 83.0% gain for the benchmark index.

There are no published analyst ratings, consensus earnings estimates, or price targets available for Firefly Neuroscience. The company's next scheduled earnings release date is November 11, 2026. For the trailing twelve months ended June 30, 2026, the company posted an EPS of -$0.59, following annual diluted EPS of -$2.64 in FY2024 and -$3.30 in FY2023. Institutional ownership stands at 10.5%, insider ownership is 9.4%, and short interest accounts for 7.4% of the float.

This page is an AI-written research summary of Firefly Neuroscience, Inc. (AIFF). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AIFF income statement, AIFF balance sheet, AIFF key metrics, AIFF chart. See the AIFF stock overview for the latest quote and news.